(12 days)
No
The summary describes a device using Scanning Laser Polarimetry for imaging and analysis, but there is no mention of AI or ML in the intended use, device description, or any other section. The analysis is based on a normative database, which is a standard statistical comparison, not necessarily AI/ML.
No
The device is described as an imaging device used for diagnosis and monitoring, and it does not mention any therapeutic function or intervention.
Yes
Explanation: The "Intended Use / Indications for Use" section explicitly states that the GDx device and its databases "aid in the diagnosis and monitoring of diseases and disorders of the eye." This directly indicates its role as a diagnostic tool.
No
The device description explicitly states it comprises an "optomechanical scanning laser head unit and a computer," indicating it includes hardware components beyond just software.
Based on the provided information, this device is not an IVD (In Vitro Diagnostic).
Here's why:
- IVD definition: In vitro diagnostics are tests performed on samples taken from the human body, such as blood, urine, or tissue, to detect diseases, conditions, or infections.
- Device function: The GDx is a scanning laser ophthalmoscope that images and analyzes the retinal nerve fiber layer in vivo (within the living body). It does not analyze samples taken from the body.
- Intended Use: The intended use clearly states it's for imaging and analysis of the fundus and RNFL in vivo.
Therefore, the GDx falls under the category of an in vivo diagnostic imaging device, not an in vitro diagnostic device.
N/A
Intended Use / Indications for Use
The GDx is a confocal polarimetric scanning laser ophthalmoscope that is intended for imaging and three-dimensional analysis of the fundus and retinal nerve fiber layer (RNFL) in vivo.
The GDx and its GDx Variable Corneal Compensation (VCC) and GDx Enhanced Corneal Compensation (ECC) RNFL Normative Databases aid in the diagnosis and monitoring of diseases and disorders of the eye that may cause changes in the polarimetric retinal nerve fiber layer thickness. The GDx is to be used in patients who may have an optic neuropathy.
Product codes
MYC, HLI
Device Description
The GDxPRO is a confocal scanning laser ophthalmoscope comprising an optomechanical scanning laser head unit and a computer. The device employs Scanning Laser Polarimetry (SLP) to measure the Retinal Nerve Fiber Layer (RNFL) thickness using polarized light.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Scanning Laser Polarimetry (SLP)
Anatomical Site
fundus and retinal nerve fiber layer (RNFL) of the eye
Indicated Patient Age Range
Not Found
Intended User / Care Setting
Not Found
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
Evaluation performed on the GDxPRO supports the indications for use statement and demonstrates that the device is substantially equivalent to the predicate device and does not raise new questions regarding safety and effectiveness.
As described in this 510(k) Summary, all testing deemed necessary was conducted on the GDxPRO to ensure that the device is safe and effective for its intended use when used in accordance with its Instructions for Use.
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Not Found
Predicate Device(s)
Reference Device(s)
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information
Not Found
§ 886.1570 Ophthalmoscope.
(a)
Identification. An ophthalmoscope is an AC-powered or battery-powered device containing illumination and viewing optics intended to examine the media (cornea, aqueous, lens, and vitreous) and the retina of the eye.(b)
Classification. Class II (special controls). The device, when it is an AC-powered opthalmoscope, a battery-powered opthalmoscope, or a hand-held ophthalmoscope replacement battery, is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 886.9.
0
SECTION 5.
- 510(K) SUMMARY
510(K) SUMMARY
- "
510 k: K093521 510(k) SUMMARY (per 21 CFR §807.92)
GDxPRO™
GENERAL INFORMATION
| Manufacturer: | Carl Zeiss Meditec Inc.
5160 Hacienda Drive
Dublin, California 94568
(925) 557-4616 (phone)
(925) 557-4259 (fax)
Est. Reg. No. 2918630 | NOV 2 5 2009 |
|-------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|
| Contact Person: | Judith A. Brimacombe, MA
Director, Clinical/Regulatory Affairs
Carl Zeiss Meditec Inc.
5160 Hacienda Drive
Dublin, California 94568
(925) 557-4616 (phone)
(925) 557-4259 (fax) | |
| Date Summary Prepared: | October 23, 2009 | |
| Regulation Number: | 21 CFR 886.1570 | |
| Classification name: | Ophthalmoscope, Laser Scanning | |
| Classification: | Class II | |
| Product Code: | MYC, HLI | |
| Trade/Proprietary name: | GDxPRO™ | |
PREDICATE DEVICE
| Company: | Carl Zeiss Meditec, Inc. |
|---|---|
| Device: | GDx with ECC Retinal Nerve Fiber Layer Normative Database (K082016) |
1
SECTION 5.
INTENDED USE
The GDx is a confocal polarimetric scanning laser ophthalmoscope that is intended for imaging and three-dimensional analysis of the fundus and retinal nerve fiber layer (RNFL) in vivo.
INDICATIONS FOR USE
The GDx is a confocal polarimetric scanning laser ophthalmoscope that is intended for imaging and three-dimensional analysis of the fundus and retinal nerve fiber laver (RNFL) in vivo. The GDx and its GDx Variable Corneal Compensation (VCC) and GDx Enhanced Corneal Compensation (ECC) RNFL Normative Databases aid in the diagnosis and monitoring of diseases and disorders of the eye that may cause changes in the polarimetric retinal nerve fiber layer thickness. The GDx is to be used in patients who may have an optic neuropathy.
DEVICE DESCRIPTION
The GDxPRO is a confocal scanning laser ophthalmoscope comprising an optomechanical scanning laser head unit and a computer. The device employs Scanning Laser Polarimetry (SLP) to measure the Retinal Nerve Fiber Layer (RNFL) thickness using polarized light.
SUBSTANTIAL EQUIVALENCE
It is the opinion of Carl Zeiss Meditec, Incorporated that the GDxPRO is substantially equivalent to the GDx with ECC Retinal Nerve Fiber Layer Normative Database as it contains modifications to the predicate that do not raise questions of safety or efficacy. The indications for use statement for the GDxPRO is exactly the same as the indications for use statement for the predicate device cited in this application. A technological comparison demonstrates that the GDxPRO is functionally equivalent to the predicate device. Both devices are intended for imaging and three-dimensional analysis of the fundus and retinal nerve fiber layer (RNFL) in vivo.
Evaluation performed on the GDxPRO supports the indications for use statement and demonstrates that the device is substantially equivalent to the predicate device and does not raise new questions regarding safety and effectiveness.
SUMMARY
As described in this 510(k) Summary, all testing deemed necessary was conducted on the GDxPRO to ensure that the device is safe and effective for its intended use when used in accordance with its Instructions for Use.
2
Image /page/2/Picture/1 description: The image shows the logo for the Department of Health & Human Services - USA. The logo features a stylized depiction of an eagle or bird-like figure with flowing lines, suggesting movement or flight. The text "DEPARTMENT OF HEALTH & HUMAN SERVICES-USA" is arranged in a circular fashion around the bird symbol.
Food and Drug Administration 10903 New Hampshire Avenue Document Mail Center - WO66-G609 Silver Spring, MD 20993-0002
Carl Zeiss Meditec, Inc. c/o Underwriters Laboratories, Inc. Mr. Ned E. Devine Sr. Staff Engineer 333 Pfingten Road Northbrook, IL 60062
NOV 2 5 2009
Re: K093521
Trade/Device Name: GDxPRO Regulation Number: 21 CFR 886.1570 Regulation Name: Ophthalmoscope Regulatory Class: II Product Code: MYC Dated: November 11, 2009 Received: November 13, 2009
Dear Mr. Devine:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (OS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
3
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please go to http://www.fda.gov/AboutFDA/CentersOffices/CDRH/CDRHOffices/ucm115809.htm for the Center for Devices and Radiological Health's (CDRH's) Office of Compliance. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to http://www.fda.gov/cdrh/mdr/ for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.
You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (240) 276-3150 or at its Internet address http://www.fda.gov/cdrl/industry/support/index.html.
Sincerely yours,
R.C. Anderson for
Malvina B. Eydelman, M Director Division of Ophthalmic, Neurological, and Ear, Nose and Throat Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
4
SECTION 4.
INDICATIONS FOR USE STATEMENT
4. INDICATIONS FOR USE STATEMENT
510(k) Number (if known): _ |